PhD student in Apoptosis Signaling & Cancer

We are seeking applications for an enthusiastic, highly motivated PhD student in the field of Apoptosis Signaling & Cancer.

The Institute for Experimental Cancer Research in Pediatrics (Director: Prof. Dr. Simone Fulda) at the Goethe-University Frankfurt to promote translational cancer research. We study cell death signaling pathways in cancers in order to identify key molecules for the development of new cancer therapeutics and novel prognostic biomarkers (e.g. Vogler M et al, Br J Haematology, 2017, 178, 364–379).

Activities and responsibilities

The current project is led by Dr. Meike Vogler and funded by the Else Kröner Fresenius Stiftung. The research question will focus on the role of BCL2 proteins in lymphoma. In particular we will study the potential of BH3 mimetics like Venetoclax as novel therapeutics and elucidate potential resistance pathways. Besides translational research questions we will also seek to elucidate molecular mechanism related to the cellular function of BCL2 proteins. This will be done by applying innovative technologies like CRISPR/Cas9 and 3D cell culture models. Successful applicants will join a supportive research team and will have the opportunity to participate in the International Graduate School in Biomedicine at Frankfurt, the German Cancer Consortium (DKTK) and in our international research networks on apoptosis (e.g. EU projects).

Qualification profile

Interested candidates must have a M.Sc. or an equivalent degree. Applicants with skills in cell and molecular biology are encouraged to apply. We are seeking candidates who are highly self-motivated to join a young, international and dynamic research team.


The position can be filled immediately, initially for 3 years with the possibility for extension.

Send application to

Dr. Meike Vogler
Institut für Experimentelle Tumorforschung in der Pädiatrie
Goethe-Universität Frankfurt
Komturstr. 3a
60528 Frankfurt/Main
E-Mail: Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!



Zum Seitenanfang
Cookies erleichtern die Bereitstellung unserer Dienste. Mit der Nutzung unserer Dienste erklären Sie sich damit einverstanden, dass wir Cookies verwenden.